Home › Compare › DCHCF vs ABBV
DCHCF yields 23.30% · ABBV yields 3.06%● Live data
📍 DCHCF pulled ahead of the other in Year 1
Combined, DCHCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DCHCF + ABBV for your $10,000?
Dainichiseika Color & Chemicals Mfg. Co., Ltd. manufactures and sells a range of pigments and colorants. It provides inorganic, organic, and processed pigments for applications, including paints, printing inks, and information display and recording materials; colorants for industries comprising mass colorants for synthetic fibers, pigmented printing agents, and colorants for paper and construction materials; and functional materials for polyvinyl chloride, high-performance fluororesin, and various thermoplastic and thermosetting resins, as well as for electronics and information materials, automotive, and interior construction materials fields. The company also offers UV and EB curable coating materials, decorative, and functional coating materials; and polyurethane and colorants used in synthetic leather and molded products, coating agents, and adhesives, as well as imide-based resins. In addition, it provides Chitosan, a polymer product made from crab shells, as well as its derivatives; functional inks and offset printing inks used in paper media, such as flyers, books, and packaging materials; gravure inks; and coating agents and flexographic printing inks. The company was founded in 1931 and is headquartered in Tokyo, Japan.
Full DCHCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.